Financials

  • Market Capitalization 11.97 B
  • Employee 711
  • Founded 2004
  • CEO Christopher Richard Anzalone
  • Website www.arrowheadpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000BRVKH0
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-3 449
Price to sales ratio
5.56

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
802
BMRN
BioMarin Pharmaceutical Inc. - Common Stock
65.29 USD-0.49%-3.29%+5.19%+13.47%12.64 B USD
807
MDGL
Madrigal Pharmaceuticals, Inc. - Common Stock
532.91 USD-1.98%+0.95%-1.60%+25.80%12.31 B USD
828
HALO
Halozyme Therapeutics, Inc. - Common Stock
104.93 USD-1.86%-2.80%+26.30%+57.08%11.91 B USD
859
TECH
Bio-Techne Corp - Common Stock
72.36 USD-0.15%+0.06%+0.32%+33.63%11.35 B USD

Frequently asked questions about Arrowhead Research Corporation

What is the Arrowhead Research Corporation stock price today?

The current price of Arrowhead Research Corporation (ARWR) is 84.72. Over the past 24 hours, the stock has changed by -4.37%. Follow the ARWR chart for real-time price dynamics.

What is the stock ticker of Arrowhead Research Corporation?

Arrowhead Research Corporation trades under the ticker ARWR. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Arrowhead Research Corporation stock going up?

ARWR has changed by -2.23% over the last week, -0.98% over the last month, and +116.68% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Arrowhead Research Corporation?

Arrowhead Research Corporation currently has a market capitalization of 11.97 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Arrowhead Research Corporation earnings last quarter?

Last quarter, Arrowhead Research Corporation reported earnings of -1.36 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Arrowhead Research Corporation revenue for the last quarter?

Arrowhead Research Corporation reported quarterly revenue of 75.25 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Arrowhead Research Corporation net income for the last quarter?

Arrowhead Research Corporation reported net income of -194.28 M for the last quarter. The previous quarter showed -132.73 M, which means net income changed by -46.37%.

How many employees does Arrowhead Research Corporation have?

As of the latest available data, Arrowhead Research Corporation has 711 employees. Workforce size can provide additional context about the company's scale and operations.

What is Arrowhead Research Corporation EBITDA?

Arrowhead Research Corporation EBITDA is -163.89 M, and its EBITDA margin is -217.79%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Arrowhead Research Corporation stock?

You can buy Arrowhead Research Corporation (ARWR) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Arrowhead Research Corporation stock?

Investing in Arrowhead Research Corporation requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ARWR chart and related analysis on metatrader.com as part of your research.

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

News